VEGF (Vascular Endothelial Growth Factor) is a protein that plays a crucial role in angiogenesis, and the formation of new blood vessels. It is primarily secreted by cells in response to tissue hypoxia and triggers a cascade of events that stimulate the growth of new blood vessels. By binding to its receptors on endothelial cells, VEGF promotes endothelial cell proliferation, migration, and permeability, facilitating the development of new blood vessels. In medicine, VEGF inhibitors are used to target and inhibit the activity of VEGF, thereby suppressing angiogenesis and reducing blood vessel growth. VEGF-based therapies are utilized in the treatment of several disease indications, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and various types of cancer such as colorectal, lung, and renal cell carcinoma. According to the World Health Organization (WHO), AMD is a leading cause of vision loss, affecting over 170 million people globally. In Europe, the prevalence of AMD is estimated to be around 7.3% among individuals aged 65 years and older. Diabetic retinopathy, a common complication of diabetes, affects approximately one-third of individuals with diabetes globally.
In the United States, it is reported that over 30 million people have diabetes, and diabetic retinopathy accounts for a significant proportion of vision loss and blindness among working-age adults. The incidence and prevalence of cancer vary across specific types and regions. For instance, colorectal cancer is the third most commonly diagnosed cancer worldwide, with approximately 1.8 million new cases reported in Europe and the United States combined. Companies such as Roche, Pfizer, HLB Bio Group, Novartis, Bayer, Eli Lilly, Sanofi, AstraZeneca, Simcere, Takeda, Bausch Health, Novartis, Outlook Therapy, Tactical Therapy, GeneScience, J&J, Komipharm, Biocon, Herantis, Celltrion, Dr. Reddy's, Sino Biopharm cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, GSK is currently conducting a clinical trial of the SU5416 for treating adenocarcinoma.
Key Developments:
- In May 2022, Roche re-initiated the phase IIIb Velodrome trial of Lucentis in Wet age-related macular degeneration (Treatment-experienced) in Germany, Austria, Argentina, Australia, Belgium, Brazil, France, Israel, Italy, South Korea, Singapore, Spain, Switzerland, Taiwan, Turkey and the United Kingdom
- In April 2021, Chugai Pharmaceutical completed enrolment in its phase II Quattro-II trials of Avastin for Colorectal cancer (Metastatic disease, First-line therapy, Combination therapy, Inoperable/Unresectable) in Japan
Approved VEGF Molecules
- Avastin (bevacizumab)
- Everolimus
- Sorafenib
- Lucentis (ranibizumab)
- Sutent (sunitinib)
- AiTan (rivoceranib)
- Lenvima (lenvatinib)
- Eylea (aflibercept intravitreal)
- Tyvyt (sintilimab)
- Focus V (anlotinib)
- Votrient (pazopanib)
- Stivarga (regorafenib)
- Cabometyx (cabozantinib tablet)
- Inlyta (axitinib)
- Nintedanib
- Cyramza (ramucirumab)
- Caprelsa (vandetanib)
- Recentin (cediranib)
- Endostar (recombinant human endostatin)
- Elunate (fruquintinib)
- Iclusig (ponatinib)
- Zaltrap (ziv-aflibercept IV)
- Sulanda (surufatinib)
- Cometriq (cabozantinib capsule)
- Macugen (pegaptanib)
- Rydapt (midostaurin)
- Beovu (brolucizumab-dbll)
- Signifor (pasireotide)
- Zepsun (donafenib)
- Lumitin (conbercept)
- Signifor LAR (pasireotide long acting release)
- Fotivda (tivozanib)
- Balversa (erdafitinib)
- Retevmo (selpercatinib)
- Aplidin (plitidepsin)
VEGF Pipeline Molecules
- Dovitinib (TKI258)
- Famitinib (SHR 1020)
- Vatalanib (PTK787)
- Sitravatinib (MGCD516)
- Semaxanib (SU5416)
- Brivanib alaninate (BMS-582664)
- lucitanib (E 3810)
- Motesanib (AMG 706)
- Vorolanib (X-82)
- Ivonescimab (AK112)
- Linifanib (ABT-869)
- Vadimezan (ASA404)
- Thrombospondin-1 mimetic (ABT-510)
- Chiauranib (CS 2164)
- Simtuzumab (GS 6624)
- Tesevatinib (KD019)
- Foretinib (GSK1363089)
- RGX-314
- VEGFR1-1084
- BI 836880
- BMS690514
- ENMD-2076
- PM8002
- Golvatinib (E7050)
- Olinvacimab (TTAC-0001)
- AL2846
- Emvododstat (PTC299)
- Glesatinib (MGCD265)
- Muparfostat (PI-88)
- Ningetinib (CT053PTSA)
- Suvemcitug (APX003)
- Tarcocimab tedromer (KSI 301)
- 601A
- PAN-90806
- RC28-E
- SB-509
- Navicixizumab (OMP-305B83)
- Triamcinolone acetonide + anti-VEGF (CLS-1003)
- CTX-009
- HA121-28
- LSTA1
- Neovasculgen (PI-VEGF165)
- OPT-302
Clinical Activity and Development of VEGF
In the VEGF space, more than 20 companies are conducting more than 300 clinical trials in this category of drugs. For instance,
- In Nov 2022, Pfizer presented efficacy data of Sunitinib in Prostrate cancer at the 47th European Society for Medical Oncology Congress (ESMO-2022)
- In March 2023, Roche presented efficacy and adverse events data from a phase II trial of Avastin in liver cancer at the 59th Annual Meeting of the American Society of Clinical Oncology
|
Product Name |
Total Studies |
|
Dovitinib (TKI258) |
60 |
|
Famitinib (SHR 1020) |
52 |
|
Vatalanib (PTK787) |
43 |
|
Sitravatinib (MGCD516) |
37 |
|
Semaxanib (SU5416) |
31 |
|
Brivanib alaninate (BMS-582664) |
28 |
|
lucitanib (E 3810) |
27 |
|
Motesanib (AMG 706) |
26 |
|
Vorolanib (X-82) |
22 |
|
Ivonescimab (AK112) |
21 |
|
Linifanib (ABT-869) |
20 |
|
Vadimezan (ASA404) |
20 |
|
Thrombospondin-1 mimetic (ABT-510) |
17 |
|
Chiauranib (CS 2164) |
16 |
|
Simtuzumab (GS 6624) |
15 |
|
Tesevatinib (KD019) |
15 |
|
Foretinib (GSK1363089) |
11 |
|
RGX-314 |
9 |
|
VEGFR1-1084 |
9 |
|
BI 836880 |
8 |
Target Indication Analysis of VEGF
VEGF (Vascular Endothelial Growth Factor) is a target indication in the field of medicine that plays a crucial role in angiogenesis, and the formation of new blood vessels. By targeting VEGF, pharmaceutical interventions aim to treat various conditions and diseases associated with abnormal blood vessel growth, such as age-related macular degeneration, diabetic retinopathy, and certain types of cancers like colorectal, lung, and renal cell carcinoma. VEGF inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors, are designed to inhibit VEGF signaling pathways, thereby reducing the formation of new blood vessels, inhibiting tumor growth, and potentially improving patient outcomes in these specific indications.
VEGF Market Regional Analysis
VEGF Market
The global VEGF market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The overall regional market analysis of VEGF in the US indicates a significant market presence and growth potential. The US market for VEGF-based therapies is well-established and highly competitive, driven by factors such as a large patient population, advanced healthcare infrastructure, and strong investment in research and development. The market is primarily dominated by established pharmaceutical companies that offer VEGF inhibitors and other related therapies. Furthermore, the increasing prevalence of diseases like age-related macular degeneration, diabetic retinopathy, and various cancers fuels the demand for VEGF-targeted interventions, contributing to market growth. The growth drivers of the VEGF market encompass several factors. Firstly, advancements in understanding the role of VEGF in angiogenesis and tumor progression have led to increased research and development activities focused on VEGF inhibitors and related therapies. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for VEGFs. These countries are increasingly adopting VEGFs due to their efficacy and potential to improve patient outcomes. On the other hand, the VEGF market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the VEGF market.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
VEGF drugs are used in the management of age-related macular degeneration (AMD), diabetic retinopathy (DR), and various types of cancer such as colorectal, lung, and renal cell carcinoma.
The growth drivers of the VEGF market encompass several factors. Firstly, advancements in understanding the role of VEGF in angiogenesis and tumor progression have led to increased research and development activities focused on VEGF inhibitors and related therapies.
The major players in this space are Roche, Pfizer, HLB Bio Group, Novartis, Bayer, Eli Lilly, Sanofi, AstraZeneca, Simcere, Takeda, Bausch Health, Novartis, Outlook Therapy, Tactical Therapy, GeneScience, J&J, Komipharm, Biocon, Herantis, Celltrion, Dr. Reddy's, Sino Biopharm.
Despite favorable market conditions, the VEGF drug market faces certain restraints. One major challenge is the high cost of VEGF inhibitors, which can limit access for patients and strain healthcare budgets. Additionally, the potential side effects and toxicity associated with VEGF inhibitors pose concerns for both patients and healthcare providers, requiring careful monitoring and management during treatment.
- Roche
- Pfizer
- HLB Bio Group
- Novartis
- Bayer
- Eli Lilly
- Sanofi
- AstraZeneca
- Simcere
- Takeda
- Bausch Health
- Novartis
- Outlook Therapy
- Tactical Therapy
- GeneScience
- J&J
- Komipharm
- Biocon
- Herantis
- Celltrion
- Reddy’s
- Sino Biopharm